Strategic Partnerships Leverage Exagen’s AVISE platform and biomarker innovations to pursue collaborations with rheumatology clinics, payers, and biopharma companies seeking advanced autoimmune diagnostics and precision management for lupus and rheumatoid arthritis.

Clinical Excellence Position Exagen’s CB-CAPS, T Cell markers, anti-PAD4, and anti-RA33 tests as differentiated offerings to improve diagnostic accuracy and disease monitoring, targeting high-value accounts that prioritize cutting-edge autoimmune testing.

Academic Alliances Capitalize on ongoing collaborations like the Johns Hopkins partnership to secure opportunities for joint studies, sponsorships, and data-sharing initiatives that expand market credibility and lead to broader adoption.

Geographic Expansion Explore international and regional expansion, noting recent facility growth signals and potential for deploying AVISE testing in new markets to meet rising demand for precise autoimmune diagnostics.

Strategic Growth Target health systems and diagnostics distributors aligned with mid-market revenue bands, leveraging Exagen’s revenue trajectory and 2026 guidance to secure multi-year procurement contracts and scalable testing programs.